Cargando…
A population-based analysis of the longevity of SARS-CoV-2 antibody seropositivity in the United States
BACKGROUND: This cross-sectional study aimed to track population-based SARS-CoV-2 antibody seropositivity duration across the United States using observational data from a national clinical laboratory registry of patients tested by nucleic acid amplification (NAAT) and serologic assays. Knowledge of...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143650/ https://www.ncbi.nlm.nih.gov/pubmed/34056568 http://dx.doi.org/10.1016/j.eclinm.2021.100902 |
_version_ | 1783696802361376768 |
---|---|
author | Alfego, David Sullivan, Adam Poirier, Brian Williams, Jonathan Adcock, Dorothy Letovsky, Stanley |
author_facet | Alfego, David Sullivan, Adam Poirier, Brian Williams, Jonathan Adcock, Dorothy Letovsky, Stanley |
author_sort | Alfego, David |
collection | PubMed |
description | BACKGROUND: This cross-sectional study aimed to track population-based SARS-CoV-2 antibody seropositivity duration across the United States using observational data from a national clinical laboratory registry of patients tested by nucleic acid amplification (NAAT) and serologic assays. Knowledge of antibody seropositivity and its duration may help dictate post-pandemic planning. METHODS: Using assays to detect antibodies to either nucleocapsid (N) or spike (S) proteins performed on specimens from 39,086 individuals with confirmed positive COVID-19 by reverse transcription-polymerase chain reaction (RT-PCR) from March 2020 to January 2021, we analyzed nationwide seropositivity rates of IgG up to 300 days following patients’ initial positive NAAT test. Linear regression identified trends in seropositivity rates and logistic regression tested positive predictability by age, sex, assay type and days post-infection. FINDINGS: Seropositivity of IgG antibodies to both SARS-CoV-2 S and N-proteins followed a linear trend reaching approximately 90% positivity at 21 days post-index. The rate of N-protein seropositivity declined at a sharper rate, decaying to 68·2% [95% CI: 63·1–70·8%] after 293 days, while S-antibody seropositivity maintained a rate of 87·8% [95% CI: 86·3–89·1%] through 300 days. In addition to antigen type and the number of days post-positive PCR, age and gender were also significant factors in seropositivity prediction, with those under 65 years of age showing a more sustained seropositivity rate. INTERPRETATION: Observational data from a national clinical laboratory, though limited by an epidemiological view of the U.S. population, offer an encouraging timeline for the development and sustainability of antibodies up to ten months from natural infection and could inform post-pandemic planning. |
format | Online Article Text |
id | pubmed-8143650 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-81436502021-05-25 A population-based analysis of the longevity of SARS-CoV-2 antibody seropositivity in the United States Alfego, David Sullivan, Adam Poirier, Brian Williams, Jonathan Adcock, Dorothy Letovsky, Stanley EClinicalMedicine Research Paper BACKGROUND: This cross-sectional study aimed to track population-based SARS-CoV-2 antibody seropositivity duration across the United States using observational data from a national clinical laboratory registry of patients tested by nucleic acid amplification (NAAT) and serologic assays. Knowledge of antibody seropositivity and its duration may help dictate post-pandemic planning. METHODS: Using assays to detect antibodies to either nucleocapsid (N) or spike (S) proteins performed on specimens from 39,086 individuals with confirmed positive COVID-19 by reverse transcription-polymerase chain reaction (RT-PCR) from March 2020 to January 2021, we analyzed nationwide seropositivity rates of IgG up to 300 days following patients’ initial positive NAAT test. Linear regression identified trends in seropositivity rates and logistic regression tested positive predictability by age, sex, assay type and days post-infection. FINDINGS: Seropositivity of IgG antibodies to both SARS-CoV-2 S and N-proteins followed a linear trend reaching approximately 90% positivity at 21 days post-index. The rate of N-protein seropositivity declined at a sharper rate, decaying to 68·2% [95% CI: 63·1–70·8%] after 293 days, while S-antibody seropositivity maintained a rate of 87·8% [95% CI: 86·3–89·1%] through 300 days. In addition to antigen type and the number of days post-positive PCR, age and gender were also significant factors in seropositivity prediction, with those under 65 years of age showing a more sustained seropositivity rate. INTERPRETATION: Observational data from a national clinical laboratory, though limited by an epidemiological view of the U.S. population, offer an encouraging timeline for the development and sustainability of antibodies up to ten months from natural infection and could inform post-pandemic planning. Elsevier 2021-05-24 /pmc/articles/PMC8143650/ /pubmed/34056568 http://dx.doi.org/10.1016/j.eclinm.2021.100902 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Research Paper Alfego, David Sullivan, Adam Poirier, Brian Williams, Jonathan Adcock, Dorothy Letovsky, Stanley A population-based analysis of the longevity of SARS-CoV-2 antibody seropositivity in the United States |
title | A population-based analysis of the longevity of SARS-CoV-2 antibody seropositivity in the United States |
title_full | A population-based analysis of the longevity of SARS-CoV-2 antibody seropositivity in the United States |
title_fullStr | A population-based analysis of the longevity of SARS-CoV-2 antibody seropositivity in the United States |
title_full_unstemmed | A population-based analysis of the longevity of SARS-CoV-2 antibody seropositivity in the United States |
title_short | A population-based analysis of the longevity of SARS-CoV-2 antibody seropositivity in the United States |
title_sort | population-based analysis of the longevity of sars-cov-2 antibody seropositivity in the united states |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143650/ https://www.ncbi.nlm.nih.gov/pubmed/34056568 http://dx.doi.org/10.1016/j.eclinm.2021.100902 |
work_keys_str_mv | AT alfegodavid apopulationbasedanalysisofthelongevityofsarscov2antibodyseropositivityintheunitedstates AT sullivanadam apopulationbasedanalysisofthelongevityofsarscov2antibodyseropositivityintheunitedstates AT poirierbrian apopulationbasedanalysisofthelongevityofsarscov2antibodyseropositivityintheunitedstates AT williamsjonathan apopulationbasedanalysisofthelongevityofsarscov2antibodyseropositivityintheunitedstates AT adcockdorothy apopulationbasedanalysisofthelongevityofsarscov2antibodyseropositivityintheunitedstates AT letovskystanley apopulationbasedanalysisofthelongevityofsarscov2antibodyseropositivityintheunitedstates AT alfegodavid populationbasedanalysisofthelongevityofsarscov2antibodyseropositivityintheunitedstates AT sullivanadam populationbasedanalysisofthelongevityofsarscov2antibodyseropositivityintheunitedstates AT poirierbrian populationbasedanalysisofthelongevityofsarscov2antibodyseropositivityintheunitedstates AT williamsjonathan populationbasedanalysisofthelongevityofsarscov2antibodyseropositivityintheunitedstates AT adcockdorothy populationbasedanalysisofthelongevityofsarscov2antibodyseropositivityintheunitedstates AT letovskystanley populationbasedanalysisofthelongevityofsarscov2antibodyseropositivityintheunitedstates |